Literature DB >> 10073847

Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy.

J A Puma1, M H Sketch, T D Thompson, R J Simes, D C Morris, H D White, E J Topol, R M Califf.   

Abstract

We examined the possible benefits of achieving and maintaining infarct-related artery potency beyond the time when preservation of left ventricular function would be expected. The open-artery hypothesis suggests that a patent infarct-related artery confers a survival benefit greater than that expected from myocardial salvage alone, which extends beyond the time when preservation of left ventricular function is expected. We examined the survival experience of patients undergoing thrombolysis in the Global Utilization of Streptokinase and TPA for Occluded Arteries (GUSTO-I) trial for whom data on the potency of the infarct artery were available. Univariable analysis was used to determine the unadjusted relations of angiographic variables and revascularization procedures to both 30-day and 1-year mortality in 30-day survivors. Multivariable analysis was used to test for interactions between patency and each characteristic and to adjust both for all other variables and for baseline characteristics known to predict mortality. In both univariable and multivariable analysis, patients with an open rather than a closed infarct-related artery had significantly lower 30-day mortality (p <0.001). This benefit cannot be accounted for by myocardial salvage alone, because it remained after adjustment for left ventricular ejection fraction. Patency was also associated with lower 1-year mortality in 30-day survivors, but not after adjustment for other variables affecting late mortality. Having an open infarct-related artery at the time of first catheterization confers a survival advantage that extends beyond the benefit of myocardial salvage from thrombolytic therapy, and is independent of ejection fraction.

Entities:  

Mesh:

Year:  1999        PMID: 10073847     DOI: 10.1016/s0002-9149(98)00899-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Benefits of late reperfusion in the treatment of acute myocardial infarction.

Authors:  Kinji Ishikawa
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

Review 2.  The open-artery hypothesis revisited.

Authors:  Alireza Zarrabi; Hossein Eftekhari; S Ward Casscells; Mohammad Madjid
Journal:  Tex Heart Inst J       Date:  2006

3.  Coronary intervention for persistent occlusion after myocardial infarction.

Authors:  Judith S Hochman; Gervasio A Lamas; Christopher E Buller; Vladimir Dzavik; Harmony R Reynolds; Staci J Abramsky; Sandra Forman; Witold Ruzyllo; Aldo P Maggioni; Harvey White; Zygmunt Sadowski; Antonio C Carvalho; Jamie M Rankin; Jean P Renkin; P Gabriel Steg; Alice M Mascette; George Sopko; Matthias E Pfisterer; Jonathan Leor; Viliam Fridrich; Daniel B Mark; Genell L Knatterud
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

4.  Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial.

Authors:  Venu Menon; Camille A Pearte; Christopher E Buller; Ph Gabriel Steg; Sandra A Forman; Harvey D White; Paolo N Marino; Demosthenes G Katritsis; Paulo Caramori; Ricardo Lasevitch; Krystyna Loboz-Grudzien; Aleksander Zurakowski; Gervasio A Lamas; Judith S Hochman
Journal:  Eur Heart J       Date:  2008-11-21       Impact factor: 29.983

5.  Left ventricular ejection fraction is determined by both global myocardial strain and wall thickness.

Authors:  David H MacIver; Ismail Adeniran; Henggui Zhang
Journal:  Int J Cardiol Heart Vasc       Date:  2015-04-06

6.  Left ventricular active strain energy density is a promising new measure of systolic function.

Authors:  David H MacIver; Peter Agger; Jonathan C L Rodrigues; Henggui Zhang
Journal:  Sci Rep       Date:  2022-07-26       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.